ImmunogenX
ImmunogenX is a privately held, clinical-stage biotherapeutics company founded in 2013 in Newport Beach, California, developing therapeutics for celiac disease and related immune-mediated conditions following its 2016 acquisition of Alvine Pharmaceuticals.
- Company typePrivate
- Founded2013
- HeadquartersNewport Beach, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ImmunogenX does
ImmunogenX is a clinical-stage biotherapeutics company founded in 2013 and headquartered in Newport Beach, California. The company operates in the biopharmaceutical sector, focused on developing therapeutic biologics, and has historically centered its pipeline on celiac disease and related immune-mediated conditions, as evidenced by its 2016 acquisition of Alvine Pharmaceuticals, a celiac-focused biotech. The company is privately held, employs between 11 and 50 people, and is led by a small executive team comprising CEO Jack A. Syage, co-founder and Chief Scientific Officer Jennifer Sealey, and Chief Operating Officer Matt Dickason.
The company's strategic activity to date has been oriented toward pipeline consolidation and non-dilutive capital formation rather than commercial revenue. In March 2016, ImmunogenX acquired Alvine Pharmaceuticals for an undisclosed amount, absorbing Alvine's celiac-disease therapeutic assets into its own development portfolio. In April 2019, the company received grant funding from the National Institute of Allergy and Infectious Diseases (NIAID), recorded at a nominal $0 valuation in the source, which likely represents non-dilutive federal research support rather than equity capital. No commercial products, pricing structures, or revenue figures are disclosed in the available source material.
The company's business model is consistent with a pre-commercial clinical-stage biotech: capital is sourced from grants and (presumably) private financing, while value creation depends on advancing therapeutic candidates through clinical milestones toward eventual licensing, partnership, or commercialization. The source data does not disclose any active commercial products, payer or provider relationships, or geographic markets served. The company's own website was inaccessible at the time of data collection (displaying only a verification/loader page), which limits further primary-source verification of pipeline status, clinical trial progression, or current operating condition.
ImmunogenX firmographics
Firmographics- Name
- ImmunogenX
- Website
- https://immunogenx.com
- Company type
- Private
- Founded year
- 2013
- Headcount range
- 11–50 employees
- Short description
- ImmunogenX is a privately held, clinical-stage biotherapeutics company founded in 2013 in Newport Beach, California, developing therapeutics for celiac disease and related immune-mediated conditions following its 2016 acquisition of Alvine Pharmaceuticals.
- Ownership category
- akta.pro rank
ImmunogenX industry classification
Industry- Product category
- Clinical-stage Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)
- akta.pro secondary industries
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)
Keywords
Where ImmunogenX is headquartered
LocationHeadquarters
- HQ city
- Newport Beach
- HQ country
- United States
- HQ region
- North America
Markets served
ImmunogenX business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Others
ImmunogenX product offering
Product offeringCore offering
ImmunogenX is a clinical-stage biotherapeutics company developing biologic therapeutics, with a primary focus on treatments for celiac disease. The company leverages immunology and biologic drug development capabilities, augmented by assets acquired from Alvine Pharmaceuticals in 2016, to advance its pipeline through clinical development.
Differentiator
Problem solved
Functional benefit
Products and services
- Alvine Pharmaceuticals Biotherapeutic Assets (Celiac Disease Pipeline) Biological drug candidates and related assets targeting celiac disease, acquired from Alvine Pharmaceuticals; intended for clinical development by ImmunogenX in the immunology/autoimmune space.
Companies that use ImmunogenX
Customer profileIdeal customer profiles1 record
ImmunogenX technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
ImmunogenX partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
ImmunogenX competitors and assessment
Company assessmentBroad incumbents
- Eli Lilly: Eli Lilly has a growing immunology franchise (Taltz, Olumiant) and active autoimmune disease R&D, making it a relevant broad incumbent comparable to ImmunogenX in the immunology space.
- Takeda Pharmaceutical: Takeda is a global pharmaceutical company with a significant gastroenterology franchise that overlaps with celiac disease therapeutics; it has historically been active in celiac disease R&D and acquired certain Alvine-related assets, positioning it as a broad incumbent in ImmunogenX's therapeutic area.
- AbbVie: AbbVie is a global biopharmaceutical company with a major immunology franchise (Humira, Skyrizi, Rinvoq). Its dominance in autoimmune and inflammatory disease therapeutics makes it a relevant broad incumbent peer for any immunology-focused biotech like ImmunogenX.
- Sanofi: Sanofi is a global pharmaceutical company with a major immunology franchise including Dupixent, and has active autoimmune and inflammatory bowel disease programs that overlap thematically with ImmunogenX's therapeutic area.
- Roche: Roche/Genentech operates one of the largest immunology pipelines in the industry (Actemra, Ocrevus, Xolair) and is a relevant broad incumbent peer for any autoimmune-focused clinical-stage company like ImmunogenX.
- Johnson & Johnson: Johnson & Johnson operates a major immunology division through Janssen (Stelara, Tremfya, Remicade) and is highly active in autoimmune disease drug development, making it a relevant broad incumbent peer.
Emerging players
- Selecta Biosciences: Selecta Biosciences is a clinical-stage immunology company developing antigen-specific tolerogenic immunotherapies for autoimmune diseases, with a technology platform that overlaps thematically with ImmunogenX's therapeutic vaccine / immunology approach.
- Provention Bio: Provention Bio is a clinical-stage biopharmaceutical company focused on immune-mediated diseases, including autoimmune indications. Its strategic positioning in autoimmune therapeutics makes it a relevant emerging peer to ImmunogenX in immunology.
Direct peers
- Anokion: Anokion is a clinical-stage immunology company developing antigen-specific immunotherapies for autoimmune diseases including celiac disease, using a related tolerance-induction platform comparable to ImmunogenX's approach.
- ImmusanT: ImmusanT is a clinical-stage biotechnology company developing a therapeutic vaccine (Nexvax2) for celiac disease, the same disease focus as ImmunogenX following the Alvine acquisition. It is the closest direct competitor in the celiac therapeutic vaccine space.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
ImmunogenX social profiles
Digital presenceImmunogenX financial estimates
Financial estimateRevenue estimate
Valuation estimate
ImmunogenX leadership team
Management profileNumber of profiles
Profiles3 records
ImmunogenX funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ImmunogenX M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ImmunogenX
What does ImmunogenX do?
ImmunogenX is a clinical-stage biotherapeutics company developing biologic therapeutics, with a primary focus on treatments for celiac disease. The company leverages immunology and biologic drug development capabilities, augmented by assets acquired from Alvine Pharmaceuticals in 2016, to advance its pipeline through clinical development.
When was ImmunogenX founded?
ImmunogenX was founded in 2013. It employs 11 to 50 people.
Where is ImmunogenX based?
ImmunogenX is headquartered in Newport Beach, United States, in the North America region.
Who are ImmunogenX's main competitors?
Broad incumbents on record are Eli Lilly, Takeda Pharmaceutical, AbbVie, Sanofi, Roche and Johnson & Johnson. Emerging players are Selecta Biosciences and Provention Bio. Direct peers are Anokion and ImmusanT.
Does ImmunogenX have an API?
No public API is recorded for ImmunogenX.
What industry is ImmunogenX in?
ImmunogenX's product category is Clinical-stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection), with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.